Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | TDO2 | P48775 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL227352 | 0.93 | CES2 (0.55) | IDO1TDO2CES2CES1HDAC4 | |
| SCHEMBL230519 | 0.89 | CES2 (0.49) | IDO1TDO2CES2CES1HDAC4 | |
| SCHEMBL230516 | 0.87 | CES2 (0.50) | IDO1TDO2CES2CES1HDAC4 | |
| SCHEMBL12065137 | 0.84 | IDO1 (0.50) | IDO1TDO2CES2CES1CNR2 | |
| SCHEMBL23882733 | 0.84 | CYP11B1 (0.46) | IDO1TDO2CES2CES1HDAC4 | |
| SCHEMBL6349980 | 0.84 | CES2 (0.45) | IDO1TDO2CES2CES1HDAC4 | |
| SCHEMBL18280131 | 0.84 | CYP11B1 (0.46) | IDO1TDO2CES2CES1HDAC4 | |
| SCHEMBL28788047 | 0.84 | BRD4 (0.49) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL28531333 | 0.84 | CES2 (0.45) | IDO1TDO2CES2CES1HDAC4 | |
| SCHEMBL30598700 | 0.84 | SMN1; SMN2 (0.52) | CNR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112654621-B | Substituted naphthyridinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-3814348-B9 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3814348-B1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3814348-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-23 | — | — | US | disclosed |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2020-04-09 | — | — | US | disclosed |
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| US-7384580-B2 | Method of preparing organomagnesium compounds | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2008-06-10 | — | — | US | disclosed |
| US-7384580-B2 | Method of preparing organomagnesium compounds | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2008-06-10 | — | — | US | disclosed |
| US-20070194468-A1 | Method of preparing organomagnesium compounds | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070194468-A1 | Method of preparing organomagnesium compounds | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2007-08-23 | — | — | US | disclosed |
| EP-1790337-A2 | Methods and compounds for treating depression and other disorders | NPS PHARMACEUTICALS, INC. (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1096926-B1 | METHODS AND COMPOUNDS FOR TREATING DEPRESSION | NPS PHARMA INC (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1096926-B1 | METHODS AND COMPOUNDS FOR TREATING DEPRESSION | NPS PHARMA INC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20040039014-A1 | Methods and compounds for treating depression and other disorders | NPS PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
| EP-1096926-A2 | METHODS AND COMPOUNDS FOR TREATING DEPRESSION | NPS PHARMACEUTICALS, INC. (US) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000002551-A2 | METHODS AND COMPOUNDS FOR TREATING DEPRESSION | NPS PHARMACEUTICALS, INC. (US) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | IDO1 1773/4885TDO2 3317/4885CES2 4302/4885 |
| US-20200109140-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | IDO1 1773/4885TDO2 3317/4885CES2 4302/4885 |
| US-20070194468-A1 | Method of preparing organomagnesium compounds | SCLY, LIG3, LIG4 | IDO1 220/4885TDO2 1539/4885CES2 2135/4885 |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | IDO1 1773/4885TDO2 3317/4885CES2 4302/4885 |
| US-10669272-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | IDO1 1773/4885TDO2 3317/4885CES2 4302/4885 |
| US-20040039014-A1 | Methods and compounds for treating depression and other disorders | GRIN1, GRIN2C, GRIN3B | IDO1 273/4885TDO2 767/4885CES2 937/4885 |
| US-10954238-B1 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | IDO1 1773/4885TDO2 3317/4885CES2 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.